氯雷他定联合孟鲁司特钠辅助布地奈德治疗对变应性鼻炎患者炎性细胞及因子表达水平的影响分析

Loratadine Combined with Montelukast Sodium and Special Auxiliary Budesonide in the Treatment of Allergic Rhinitis in Patients with Inflammatory Cells and the Expression Levels of the Comparative Analysis

目的研究氯雷他定联合孟鲁司特钠辅助布地奈德对老年季节性变应性鼻炎患者鼻腔EOS阳性率、IgE及炎性因子水平的影响。方法选择2014年1月至2015年12月在我院接受治疗的老年季节性变应性鼻炎患者160例。用随机数表法分为对照组和实验组,每组各80例,对照组患者给予布地奈德鼻喷剂治疗,实验组患者在对照组的基础上加用氯雷他定和孟鲁司特钠治疗。比较两组患者的症状评分、鼻腔EOS阳性率、血清特异性IgE和血清炎性因子水平。结果治疗后两组患者的鼻塞、流涕、鼻痒、喷嚏症状评分明显降低,实验组患者的以上评分低于对照组(P<0.05)。治疗后两组患者的鼻腔EOS阳性率和血清特异性IgE水平明显下降,实验组患者的鼻腔EOS阳性率和血清特异性IgE水平低于对照组(P<0.05)。治疗后两组患者的IL-6、IL-8水平明显降低,IL-10水平升高,实验组患者的炎性因子水平变化更明显(P<0.05)。两组患者在治疗过程中未见明显不良反应,治疗后4周肝、肾功能正常。结论氯雷他定联合孟鲁司特钠辅助布地奈德可以明显缓解老年季节性变应性鼻炎患者的症状,降低血清特异性IgE及鼻腔内分泌EOS阳性率,减轻炎症反应。

Objective To study the effect of loratadine, Montelukast combined with budesonide on positive rate of IgE and nasal EOS and the level of inflammatory factors in elderly patients with seasonal allergic rhinitis. Methods A total of 160 cases of elderly patients with seasonal allergic rhinitis who treated in our hospital were selected from January 2014 to December 2015. They were divided into control group and experimental group using a random number table method, each group had 80 cases, the control group were treated with budesonide nasal spray, the experimental group were treated with loratadine and montelukast sodium on the basis of control group. We compared the symptom scores, nasal EOS positive rate, serum specific IgE and inflammatory factors between the two groups. Results After treatment, patients with nasal congestion, runny nose, nasal itching, sneezing symptom score in both groups decreased, the above scores of experimental group were lower than control group （ P 〈 0.05 ）. After treatment, the positive rate of nasal EOS and serum specific IgE levels in the two groups were significantly decreased. The positive rate of nasal EOS and the level of serum specific IgE in the experimental group were lower than those in the control group（P 〈 0.05 ）. The levels of IL-6 and IL-8 were significantly decreased in both two groups after treatment, and the levels of IL-10 in the experimental group were significantly higher than that in theexperimental group （ P 〈 0.05 ）. The treatment process in both groups had no obvious adverse reactions after treatment for 4 weeks. Conclusion Loratadine and Montelukast combined with budesonide can obviously relieve the symptoms in elderly patients with seasonal allergic rhinitis, reduce serum specific IgE and nasal endocrine EOS positive rate, and reduce inflammation.